A Phase 1, Two Period Crossover Study to Assess the Effect of a High Fat Meal on the Pharmacokinetics of Surufatinib in Healthy Subjects
Latest Information Update: 26 May 2021
At a glance
- Drugs Surufatinib (Primary)
- Indications Biliary cancer; Neuroendocrine tumours; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
Most Recent Events
- 20 May 2021 Status changed from active, no longer recruiting to completed.
- 07 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
- 07 Nov 2020 Planned primary completion date changed from 30 Nov 2020 to 1 Dec 2020.